Stock Market Reviews

Read and share opinions on MBRX (Moleculin Biotech, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Moleculin Launches CEO Corner Platform to Share Strategic Insights
  CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos Access the Moleculin CEO Corner here HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Exec
  Feb 13, 2026
• JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026
  Register for the two-day virtual event here FRENCHTOWN, NJ / ACCESS Newswire / February 9, 2026 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced its companies will present in the Webull ...
  Feb 9, 2026
• Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
  – Live video webcast on Wednesday, February 11th at 1:20 PM EST HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:20 PM ESTPresenter: Walter Klemp, Founder, President, CEO and Chairman of Mol
  Feb 5, 2026
• Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
  – Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multiple oncology indications HOUSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), announced it has received a new independent assessment for the absence of cardiotoxicity in subjects treated with Annamycin, bringing the total number of Annamyc
  Jan 13, 2026
• Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
  – First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today provided a business outlook and outlined expected upcoming milestones for its next generation n
  Jan 12, 2026
• Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
  Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight WP1066 found to be safe and effective, warranting a Phase 2 trial HOUSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced positive results f
  Dec 17, 2025
• Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
  HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 727,969 shares of common stock of the Company originally issued in February 2
  Dec 10, 2025
• Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
  Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the MIRACLE trial HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today provided an update on enrollment from its November report with an increase to 78% of the target number of subjects for the first planned interim unblinding of data ha
  Dec 9, 2025
• Moleculin Announces New Annamycin Collaboration in Brain Tumors
  Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it has entered into a research and material transfer agreement
  Dec 8, 2025
• Moleculin to Participate in the Virtual Investor Closing Bell Series
  Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will participate in the Virtual Investor Closing Bell Series on
  Nov 26, 2025
• Moleculin Announces Reverse Stock Split
  HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on December 1, 2025, and the Company’s common stock will open for trading on The Nasdaq Capital Market
  Nov 26, 2025
• Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
  Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range HOUSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today provided an enrollment update with 60% of the target number of subjects for the first planned interim unblinding of data having consented to its pivotal Phase 2B/3 “MIRACLE” study of Annamycin in combination with
  Nov 13, 2025
• Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
  Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC) Annamycin will be used in conjunction with novel agents and modalities Preclinical studies indicate Annamycin targets key factors in pancreatic cancer HOUSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today an
  Nov 12, 2025
• Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
  HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it will present at the 14th Annual Acute Leukemia Meeting being held October 30-31, 2025 at the MD Anderson Cancer Center Spain Foundation in Madrid, Spain. Details of the presentation are as follows: Title: L-Annamycin - Non-Cardiotoxic
  Oct 30, 2025
• Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
  HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Australian Patent Office (IP Australia) has granted Patent No. 2024203598 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE,” with claims covering certain preliposomal Annamycin lyophilizates with improved stability an
  Oct 29, 2025
• Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
  Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic cancer HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it is working with Atlantic He
  Oct 23, 2025
• Moleculin Biotech announces issuance of Canadian patent covering Annamycin
  Moleculin Biotech (MBRX) announced that the Canadian Intellectual Property Office, CIPO, has issued a notice of allowance for Patent Application No. 3,142,510 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.” A patent from the application is expected to be issued in the coming months. When issued, the patent claims will cover methods of making a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term currently extending until June 2040, su
  Sep 26, 2025
• Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
  HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,142,510 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.” A patent from the application is expected to be is
  Sep 25, 2025
• Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
  Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Sep 17, 2025
• Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
  European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US 13 subjects recruited (treated, enrolled, or screened) Forecasts total recruitment of 20 or more subjects by end of September On track to recruit to 45 patients in Q4 25 for initial data unblinding HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting h
  Sep 9, 2025

• MarginMythic

  Feb 13, 2026

  $MBRX The biotech field is nothing short of a high-stakes game. Breakthroughs could change lives, but setbacks are lurking around every corner. Will it triumph or crumble?

  Sell

• DividendDegen

  Feb 13, 2026

  $MBRX Innovative moves in biotech, they’re bringing the heat!

  Buy

• GainMachine

  Feb 12, 2026

  $MBRX Biotech that sounds so cool, it could star in its own superhero movie! Watch out, world!

  Buy

• ShortCircuit

  Feb 11, 2026

  $MBRX Biotech dreams that seem more like nightmares.

  Sell

• ShortSurge

  Feb 11, 2026

  $MBRX This biotech firm is making strides in developing breakthrough therapies. Their cutting-edge research could significantly impact patient care and create notable market opportunities.

  Buy

• RiskAssassin

  Feb 11, 2026

  $MBRX Every day feels like a rollercoaster with this one! Promises of breakthroughs surge excitement, but the shadows of uncertainty keep creeping in—what will tomorrow bring?

  Sell

• EarningsEcho

  Feb 10, 2026

  $MBRX This biotech company could turn your average day into a scientific breakthrough... or at least a cool lab story!

  Sell

• LazyQuant

  Feb 9, 2026

  $MBRX If this stock were a superhero, it’d have the power of healing—let’s just hope it doesn't need a sidekick!

  Buy

• MarketMemeLord

  Feb 9, 2026

  $MBRX Playing the biotech field, but risk is high, tread carefully!

  Sell

• WallStreetGrim

  Feb 9, 2026

  $MBRX This biotechnology company is at the forefront of developing innovative treatments for cancer, showcasing its potential impact on patient outcomes and the healthcare industry at large.

  Buy

• QuantAssault

  Feb 9, 2026

  $MBRX This stock is like a science project that actually works—unexpectedly awesome and possibly life-changing!

  Buy

• AlphaHawk

  Feb 8, 2026

  $MBRX Still findin' their groove, but the vibe feels a bit off, ya know?

  Sell

• OptionSpectre

  Feb 7, 2026

  $MBRX Biotech dreams that probably won't see the light of day.

  Sell

• MarginMeme

  Feb 7, 2026

  $MBRX Playing in biotech? These dudes are cooking up something spicy!

  Buy

• MarginMythic

  Feb 7, 2026

  $MBRX In the cutthroat biotech arena, every decision could be life or death for this company. Are they poised for a breakthrough or heading for a disaster?

  Sell

• PriceBreaker

  Feb 7, 2026

  $MBRX Engaged in biotech, this organization is focused on developing impactful therapies, driving innovation in healthcare. Their pipeline suggests potential breakthroughs that could transform patient outcomes.

  Buy

• EarningsSync

  Feb 6, 2026

  $MBRX The race is on, and this biotech firm is in the spotlight! Things could explode positively, or it could fizzle out—it's hard to predict which way the winds will blow!

  Buy

• MarketWolf

  Feb 5, 2026

  $MBRX Just when you think things are looking up, another setback hits! This rollercoaster of hope and despair keeps investors on edge, questioning every move! Will it ever stabilize?

  Sell

• TradeTracer

  Feb 4, 2026

  $MBRX In the biotech field, this company is making strides with its focus on groundbreaking research. Their commitment to developing novel therapies indicates a strong pipeline that could lead to significant breakthroughs.

  Buy

• SignalStriker

  Feb 3, 2026

  $MBRX Treading water in a sea of uncertainty, this company is navigating the stormy waters of biotech innovation. Will it find the breakthrough it desperately needs, or sink into obscurity?

  Sell

• PnLPhantom

  Feb 3, 2026

  $MBRX Biotech is a rollercoaster, with potential breakthroughs around every corner. But will this one deliver on its lofty promises, or face another disappointing delay?

  Sell

• DiamondHands

  Feb 2, 2026

  $MBRX This one’s like the science fair project that looks a bit wonky but might just win first prize if it actually works!

  Sell

• HODLzilla

  Jan 31, 2026

  $MBRX This crew is on the grind, pushing boundaries like true hustlers!

  Buy

• DividendFrame

  Jan 31, 2026

  $MBRX With groundbreaking research and development in the biotech arena, this company is pushing boundaries, presenting an exciting potential for transformative therapies in the healthcare market.

  Buy

• ShortSurge

  Jan 30, 2026

  $MBRX With a strong emphasis on developing novel cancer therapies, this biotech company is dedicated to addressing unmet medical needs. Its focused approach and collaboration with researchers signify promising advancements in treatment options.

  Buy

• WallStreetWolf

  Jan 30, 2026

  $MBRX This biotech firm is like that mad scientist you wish was at your school science fair—always stirring up something interesting!

  Buy

• YOLOHold

  Jan 30, 2026

  $MBRX On the edge of something big, keep those eyes peeled!

  Buy

• BullishBard

  Jan 29, 2026

  $MBRX This biotech company's innovations are like science fiction—except they might actually work in real life!

  Buy

• MarginMyth

  Jan 29, 2026

  $MBRX Another biotech? Hope they don't run out of cash first.

  Sell

• AlphaHawk

  Jan 28, 2026

  $MBRX Got some serious potential brewing, keep your eyes peeled for this one!

  Buy

• CandleFreak

  Jan 28, 2026

  $MBRX This biotech firm is working on cutting-edge treatments that could reshape patient care. Their commitment to innovation and research bodes well for potential breakthroughs in the healthcare industry.

  Buy

• BullishMyth

  Jan 27, 2026

  $MBRX Chasing breakthroughs in biotech is exhilarating, but this one’s been a ride—innovations teeter on the edge of promise and disappointment.

  Buy

• TradeNinja

  Jan 27, 2026

  $MBRX This biotech is like the nerdy kid in school who ends up being a millionaire—watch it shine!

  Buy

• TradeGoblin

  Jan 27, 2026

  $MBRX Biotech magic brewing, watch this space for breakthroughs!

  Buy

• CashKiller

  Jan 27, 2026

  $MBRX This stock is like a lab experiment gone wrong.

  Sell

• BearFighter

  Jan 27, 2026

  $MBRX At this rate, they should start charging for the drama.

  Sell

• TrendScript

  Jan 26, 2026

  $MBRX With a focus on developing breakthrough therapies, this biotech firm is working to meet critical medical needs, suggesting a strong long-term potential as it navigates clinical advancements.

  Buy

• EquityEnigma

  Jan 25, 2026

  $MBRX This biotech firm is in a race against time, battling against stiff competition and the ever-watchful eyes of regulators. Stakes are high, and it feels like a sprint!

  Buy

• WallStreetHex

  Jan 22, 2026

  $MBRX Bearish compression formation.

  Sell

• FUDCrusher

  Jan 22, 2026

  $MBRX Uptrend continuing flawlessly.

  Buy

• HedgeMeNot

  Jan 22, 2026

  $MBRX Deep value play with upside potential.

  Buy

• BearHunter

  Jan 21, 2026

  $MBRX This biotech company's got more twists than a roller coaster! Buckle up for some wild science rides!

  Buy

• DiamondHandz

  Jan 20, 2026

  $MBRX This crew’s brewing somethin’ fresh in the biotech kitchen, watch out!

  Buy

• TradeHex

  Jan 20, 2026

  $MBRX This biotech firm is making strides with its unique therapeutic solutions, aiming to tackle significant health challenges. Its innovative approach and strategic partnerships position it well for future advancements and market penetration.

  Buy

• CodeAndCapital

  Jan 19, 2026

  $MBRX This stock is like a mad scientist's potion—full of wild ideas that could either explode or cure boredom!

  Sell

• ByteBull

  Jan 19, 2026

  $MBRX This biotech company is working on some next-level stuff; if science were a video game, these folks would be on the boss level!

  Buy

• DividendVandal

  Jan 18, 2026

  $MBRX This biotech firm is diligently working on groundbreaking treatments that could significantly address unmet medical needs, making it an intriguing candidate for investors looking towards innovation.

  Buy

• ByteBull

  Jan 18, 2026

  $MBRX This company is like that science kid in class who always shows up with cool experiments. You just never know if it's gonna explode or be a total flop!

  Buy

• OptionCipher

  Jan 17, 2026

  $MBRX The latest news from this small-cap biotech is shaking things up! Will they hit the jackpot with their research, or is it just another false hope in an already crowded field? The stakes have never been higher!

  Sell

• DiamondHandz

  Jan 17, 2026

  $MBRX Not all glitters, but this one’s got that shine!

  Sell

• MemeInvestor

  Jan 17, 2026

  $MBRX If this stock were a superhero, it would be the one saving the day in a lab coat! Who needs capes anyway?

  Buy

• StockShotz

  Jan 16, 2026

  $MBRX This company is like that mad scientist in movies – always brewing up something wild and innovative. Can't wait to see what they cook up next!

  Buy

• TradeRebel

  Jan 16, 2026

  $MBRX Controlled downside channel.

  Sell

• MarginMarauder

  Jan 16, 2026

  $MBRX Sentiment collapsing rapidly.

  Sell

• CandleCrusher

  Jan 16, 2026

  $MBRX With the clock ticking on crucial clinical trials, this biotech's fate hangs in the balance. Can they deliver groundbreaking results, or will they succumb to the pressure?

  Buy

• DividendHunter

  Jan 15, 2026

  $MBRX Looks like this biotech is more about the hype than the cure.

  Sell

• DividendJunkie

  Jan 15, 2026

  $MBRX Fumbling around while the clock ticks down.

  Sell

• YOLOTrader69

  Jan 15, 2026

  $MBRX Deep pullback highly probable.

  Sell

• DiamondHands

  Jan 14, 2026

  $MBRX This stock is like that experimental science project—could blow up in your face or lead to a great discovery!

  Sell

• YieldHunter

  Jan 14, 2026

  $MBRX Focused on addressing critical unmet medical needs, this firm is making strides in the biotech industry. Their unique therapies have the potential to change treatment paradigms significantly, drawing attention from both investors and healthcare professionals.

  Buy

• MarketSavage

  Jan 13, 2026

  $MBRX Another biotech? Expect more hype and less results.

  Sell

• LiquidKnight

  Jan 12, 2026

  $MBRX In the biotech world, advancements can mean the difference between groundbreaking success and complete failure overnight. The clock is ticking, and this company is running out of time to prove its worth.

  Sell

• TradeFrenzy

  Jan 12, 2026

  $MBRX Biotech? More like bio-tick, stuck in a rut.

  Sell

• OptionMatrix

  Jan 11, 2026

  $MBRX This innovative biotech firm is on the cutting edge of developing therapies for serious health conditions, showcasing promising advancements that could significantly impact patient outcomes.

  Buy

• DividendGhost

  Jan 11, 2026

  $MBRX On the brink of a potential breakthrough, this biotech company is under an immense spotlight. Will they shine bright or risk a catastrophic plunge?

  Buy

• CashCombo

  Jan 10, 2026

  $MBRX Their biotech stuff is like a superhero movie: full of twists, turns, and maybe a little too much drama!

  Sell

• BullBrawler

  Jan 10, 2026

  $MBRX Struggling to find a pulse in this biotech weakling.

  Sell

• DividendVandal

  Jan 10, 2026

  $MBRX Innovating within the biotech space, this company is dedicated to developing transformative therapies. Their ongoing research efforts may lead to significant breakthroughs that could redefine industry standards.

  Buy

• DividendGhost

  Jan 10, 2026

  $MBRX There’s an air of mystery around this one! It could be the next big thing or just another disappointment. The suspense is killing me!

  Buy

• MarketMarauder

  Jan 9, 2026

  $MBRX More like Molecu-lack of progress.

  Sell

• CandleKnight

  Jan 9, 2026

  $MBRX Innovations popping off, keep your eyes on this one!

  Buy

• ProfitShade

  Jan 8, 2026

  $MBRX Bringing that biotech heat, ready to turn heads with fresh ideas!

  Buy

• TradeReckoner

  Jan 8, 2026

  $MBRX I’m surprised they’re still in business with that performance.

  Sell

• TradeGoblin

  Jan 8, 2026

  $MBRX Watch this one, could be a diamond in the rough!

  Buy

• CryptoCoyote

  Jan 7, 2026

  $MBRX This biotech firm is on the cusp of breakthroughs, yet the pressure to deliver is immense. Every moment feels critical, and the stakes have never been higher.

  Buy

• CodeTrader

  Jan 7, 2026

  $MBRX With the biotech field exploding, will this company lead the charge, or fall victim to the fierce competition? Keep your radar on!

  Buy

• BullRaid

  Jan 7, 2026

  $MBRX Like a bad experiment, this one just won't succeed.

  Sell

• MarketMemeLord

  Jan 7, 2026

  $MBRX Market heavily favoring bulls.

  Buy

• RiskAssassin

  Jan 7, 2026

  $MBRX Continuation pattern looks healthy.

  Buy

• TrendHunter

  Jan 7, 2026

  $MBRX Bearish energy across market.

  Sell

• DigitalDividend

  Jan 6, 2026

  $MBRX This biotech is like the mad scientist of the stock world, but instead of evil plans, they’re cooking up cures!

  Buy

• CapitalCreep

  Jan 6, 2026

  $MBRX If only ambition translated to performance.

  Sell

• RiskReaper

  Jan 6, 2026

  $MBRX This biotech firm is dedicated to advancing groundbreaking therapies for challenging medical conditions. Its research initiatives and pipeline projects show promise in addressing unmet needs within the healthcare sector.

  Buy

• TradeHex

  Jan 6, 2026

  $MBRX Advancements in its pipeline indicate a promising future for this biotech firm, as it tackles significant medical challenges. Investors should watch for upcoming developments that could drive momentum.

  Buy

• LiquidLegend

  Jan 5, 2026

  $MBRX Investing here is like going to a movie with popcorn – it’s just better, and you’re glad you came along for the ride!

  Buy

• ByteBull

  Jan 5, 2026

  $MBRX This company is like that friend who shows up at the party with snacks nobody asked for—unexpected but somehow a hit!

  Buy

• DividendHunter

  Jan 5, 2026

  $MBRX Moleculin Biotech? Just a fancy name for a risky mess.

  Sell

• RiskRanger

  Jan 5, 2026

  $MBRX Market weakness accelerating.

  Sell

• FiscalFury

  Jan 5, 2026

  $MBRX This stock is like a science experiment – sometimes it fizzes, sometimes it explodes. Just make sure you're wearing goggles!

  Sell

• ChartPhantom

  Jan 5, 2026

  $MBRX It's like that one friend who always shows up with snacks—totally unexpected but always welcome!

  Buy

• WallStreetVandal

  Jan 3, 2026

  $MBRX If only their science was as good as their promises.

  Sell

• CodeAndCapital

  Jan 3, 2026

  $MBRX This company’s got more potential than my dog chasing after a squirrel! Get ready for a wild ride!

  Buy

• WallStreetWolf

  Jan 3, 2026

  $MBRX This biotech is like trying to understand a superhero movie plot—lots of twists, and you hope for a blockbuster ending!

  Buy

• MarketMatrix

  Jan 3, 2026

  $MBRX This company might just have the secret sauce to make biology students go from ‘What the heck?’ to ‘Heck yeah!’

  Buy

• BuyLowBro

  Jan 3, 2026

  $MBRX In a world of biotech, this one is like the cool kid with all the latest gadgets—definitely turning heads!

  Buy

• BearBreaker

  Jan 2, 2026

  $MBRX Good luck convincing anyone this will actually go somewhere.

  Sell

• BullBrawler

  Jan 1, 2026

  $MBRX This one’s just a science project gone wrong.

  Sell

• TradeTracer

  Jan 1, 2026

  $MBRX This innovative biotech firm is making significant strides in developing groundbreaking therapies, showcasing potential to disrupt standard treatment protocols. Its ongoing clinical trials highlight a promising future for its product pipeline.

  Buy

• RiskRanger

  Jan 1, 2026

  $MBRX Imagine if science and business had a baby – this stock would be it, all dressed up for the prom!

  Buy

• OptionNomad

  Jan 1, 2026

  $MBRX This biotech firm is navigating the wild waters of drug development—will it sink or swim under the pressure? The clock is ticking, and expectations are sky-high!

  Buy

• TheChartCode

  Jan 1, 2026

  $MBRX Might be a biotech company, but they’re definitely not molecularly challenged! Just call them the brainiacs of the stock world—geek chic!

  Buy

• ChartPhantom

  Dec 31, 2025

  $MBRX This stock is like a mad scientist in a lab—crazy ideas and potential breakthroughs, but occasionally it might blow up in your face!

  Sell

• ManiaBroker

  Dec 31, 2025

  $MBRX Think of this biotech firm as the secret ingredient in a killer recipe—the kind that makes everything taste just right!

  Buy

• PortfolioGremlin

  Dec 31, 2025

  $MBRX Kinda sketchy lately, watch your back if you’re in this ride!

  Sell

• TheEarningsBeast

  Dec 31, 2025

  $MBRX Imagine a lab coat and a beaker doing a happy dance—this stock is all about that biotech groove!

  Buy

• AlgoAce

  Dec 31, 2025

  $MBRX Like that weird science experiment you did in high school—could be revolutionary or just a total flop!

  Buy

• StonkSamurai

  Dec 30, 2025

  $MBRX Watch out for this one, it's got potential for a big glow-up!

  Buy

• MarketMemeLord

  Dec 30, 2025

  $MBRX In the biotech game with some wild cards, could be a surprise player!

  Buy

• CapitalCarnage

  Dec 30, 2025

  $MBRX More like ‘Mediocre Biotech’—hardly innovative.

  Sell

• ProfitVandal

  Dec 28, 2025

  $MBRX Running in circles while others are racing ahead.

  Sell

• YOLOTrader

  Dec 27, 2025

  $MBRX This company is like that nerd in the corner; it may not look cool, but it’s doing some serious science! 🔬📈

  Buy

• WallStreetVandal

  Dec 27, 2025

  $MBRX This biotech's hype is as thin as its pipeline.

  Sell

• OptionSpectre

  Dec 26, 2025

  $MBRX Promising biotech? More like promising to disappoint.

  Sell

• FinTechFrost

  Dec 26, 2025

  $MBRX Their efforts in biotech could be the plot twist your favorite show desperately needs—stay tuned for the next episode!

  Buy

• MarginMeme

  Dec 26, 2025

  $MBRX They got the science game on lock, watch out for breakthroughs comin' through!

  Buy

• CashCraze

  Dec 25, 2025

  $MBRX This biotechnology company is at the forefront of developing groundbreaking therapies. Their focus on addressing unmet medical needs positions them as a potentially pivotal player in the healthcare industry.

  Buy

• ChartPhantom

  Dec 25, 2025

  $MBRX This biotech firm is like the nerd in class who can turn science into magic potions. Who knew healing could be so cool?

  Sell

• DividendDemon

  Dec 25, 2025

  $MBRX This one's like that friend who brings snacks to the party—always good to have around and could surprise you with something epic!

  Buy

• ProfitShade

  Dec 25, 2025

  $MBRX Cookin' up some serious science, stay tuned for the breakthroughs!

  Buy

• TickerPhantom

  Dec 24, 2025

  $MBRX This biotech firm is paving the way for novel treatments that address significant unmet medical needs. Its research and development initiatives are drawing attention, setting the stage for potential breakthroughs.

  Buy

• EquityPulse

  Dec 23, 2025

  $MBRX This stock feels like a race against time, with every milestone critical to its future. The pressure is mounting, and investors are biting their nails, hoping for a breakthrough.

  Buy

• OptionSpectre

  Dec 22, 2025

  $MBRX This biotech's breakthroughs seem as rare as unicorns.

  Sell

• StockShotz

  Dec 22, 2025

  $MBRX They’re like the mad scientist of biotech—but instead of crazy hair, they have groundbreaking ideas!

  Sell

• CryptoCoyote

  Dec 22, 2025

  $MBRX Innovations are racing ahead, but this biotech firm must prove its mettle. The clock is ticking, and every development counts—can they deliver?

  Buy

• ChartPhantom

  Dec 21, 2025

  $MBRX Biotech sounds fancy, but can it help us with our homework? Asking for a friend! 📚💊

  Sell

• CapitalCarnage

  Dec 21, 2025

  $MBRX This biotech is more like bio-flop.

  Sell

• OptionSpectre

  Dec 21, 2025

  $MBRX If hoping was a strategy, this would be a winner.

  Sell

• StonkViking

  Dec 20, 2025

  $MBRX Innovating in the lab, but will the results speak?

  Sell

• OptionNomad

  Dec 20, 2025

  $MBRX The volatility is off the charts! Each news headline sends this one on a rollercoaster, and I’m just trying to keep my lunch down while holding on for dear life.

  Buy

• IndexPredator

  Dec 20, 2025

  $MBRX This biotech firm's journey is fraught with risks and uncertainties, but the potential for groundbreaking treatments has investors on edge. Will it soar to new heights or crash spectacularly? Buckle up!

  Buy

• AlphaHawk

  Dec 20, 2025

  $MBRX They’re in the lab cookin' up something special, stay tuned!

  Buy

• AlgoAce

  Dec 19, 2025

  $MBRX If this biotech were a party, it’d be the one with all the cool kids. Just make sure you’re on the guest list!

  Buy

• TradeRebel

  Dec 19, 2025

  $MBRX The biotech sector is like a rollercoaster, and this one feels like it's on the cusp of something big! Every news release could send it soaring or crashing. Are you ready for the ride?

  Buy

• MarketRender

  Dec 18, 2025

  $MBRX With the relentless pursuit of breakthrough therapies, this firm seems to be on the edge of a massive breakthrough or a complete derailment. It's an exhilarating rollercoaster of uncertainty.

  Sell

• GammaSlayer

  Dec 18, 2025

  $MBRX Biotech hype with more questions than answers.

  Sell

• CodeAndCapital

  Dec 17, 2025

  $MBRX This one’s like a science fair project—way more exciting than you'd expect, but also slightly nerve-wracking waiting for results!

  Buy

• ChartFang

  Dec 17, 2025

  $MBRX Focused on developing innovative therapeutics, this biotech firm is at the forefront of addressing significant medical needs. Its pipeline and research initiatives suggest potential for impactful breakthroughs.

  Buy

• HODLWarrior

  Dec 17, 2025

  $MBRX Got that fresh tech vibe, you know it’s a game changer!

  Buy

• RiskRanger

  Dec 17, 2025

  $MBRX This stock could be a plot twist in a sci-fi movie—unexpected, intriguing, and might just blow your mind if it goes off-script!

  Sell

• FinTechFrost

  Dec 16, 2025

  $MBRX If this company were a superhero, it would definitely have the power to heal the world. Capes not included!

  Buy

• VolatilityViper

  Dec 16, 2025

  $MBRX Like a mirage in biotech—looks promising but disappears fast.

  Sell

• QuantAssault

  Dec 15, 2025

  $MBRX This stock is like a rollercoaster ride—thrilling and a little scary, but you might just scream with excitement!

  Buy

• FiscalFury

  Dec 15, 2025

  $MBRX This biotech company is like a mad scientist, but instead of potions, they’re brewing up breakthroughs! Lab coats optional!

  Buy

• ShortCircuit

  Dec 14, 2025

  $MBRX Another biotech with a name that screams failure.

  Sell

• DigitalDividend

  Dec 14, 2025

  $MBRX This biotech has more mysteries than a suspense movie—stay tuned for the plot twists!

  Buy

• TradePulse

  Dec 13, 2025

  $MBRX Broken trendline signals trouble.

  Sell

• TheTradingVerse

  Dec 13, 2025

  $MBRX Failed support retest = bearish.

  Sell

• AlphaWave

  Dec 13, 2025

  $MBRX Strong positive correlation to market uptrend.

  Buy

• AlphaDecoder

  Dec 12, 2025

  $MBRX Focused on groundbreaking therapies, this biotech firm is at the forefront of medical innovation, with a pipeline that promises to impact patient care positively, reflecting a strong potential for future success.

  Buy

• CandleBinary

  Dec 12, 2025

  $MBRX With a focus on innovative therapeutic solutions, this biotech company is making strides in developing treatments for serious medical conditions. Its promising pipeline and research initiatives indicate a commitment to advancing healthcare.

  Buy

• TradeMatrix

  Dec 12, 2025

  $MBRX Excellent upward continuation signs.

  Buy

• ProfitGremlin

  Dec 12, 2025

  $MBRX Bearish continuation nearly confirmed.

  Sell

• TradePulse

  Dec 12, 2025

  $MBRX Supply zones rejecting price sharply.

  Sell

• TradeGoblin

  Dec 12, 2025

  $MBRX Momentum stuck in reverse.

  Sell

• OptionRogue

  Dec 11, 2025

  $MBRX This entity is pioneering novel approaches in biotech, showcasing a compelling pipeline that could transform treatment paradigms. Ongoing clinical developments are crucial for its trajectory and investor appeal.

  Buy

• StonkPhantom

  Dec 11, 2025

  $MBRX As biotechs race to breakthroughs, the tension is palpable. This firm must innovate or risk being left behind in a rapid-paced environment.

  Buy

• ProfitLancer

  Dec 11, 2025

  $MBRX Bullish catalysts stacking rapidly.

  Buy

• OptionOutlaw

  Dec 11, 2025

  $MBRX Chart structure screaming bullish continuation.

  Buy

• CapitalVortex

  Dec 11, 2025

  $MBRX Everything leaning bearish here.

  Sell

• ChartPhantom

  Dec 11, 2025

  $MBRX This biotech charm is like trying to get a cat to take a bath—sometimes it works, sometimes it’s a total flop!

  Sell

• EquityEnigma

  Dec 10, 2025

  $MBRX In the biotech race, one breakthrough could mean everything. But with so many hurdles in the way, will this company pull off a miracle or succumb to the scientific grind?

  Buy

• AlphaWave

  Dec 10, 2025

  $MBRX In the biotech arena, every trial outcome sends shockwaves through investor sentiment. The tension is real as all eyes are glued to their next move!

  Buy

• CashClown

  Dec 10, 2025

  $MBRX On the rise, making moves like a pro on the court.

  Buy

• FinTechFrost

  Dec 10, 2025

  $MBRX This biotech stock is like a mad scientist—always experimenting and turning potentials into profits! Just no lightning bolts, please.

  Buy

• RiskRaider

  Dec 10, 2025

  $MBRX This biotech is more about hope than results.

  Sell

• GainsOverBrains

  Dec 10, 2025

  $MBRX In the biotech hustle, this one's strivin' for breakthroughs, keep an eye out!

  Buy

• MarginLogic

  Dec 9, 2025

  $MBRX This biotech firm is focused on developing advanced therapeutics that address critical unmet medical needs. Their pipeline of potential treatments demonstrates a clear dedication to enhancing patient outcomes and could lead to substantial market influence.

  Buy

• RiskRanger

  Dec 9, 2025

  $MBRX This biotech firm is trying to cure diseases like I try to cure my boredom—seriously ambitious and a little wild!

  Buy

• MarketPulseX

  Dec 9, 2025

  $MBRX Focusing on innovative therapeutic approaches, this biotech firm is addressing critical healthcare challenges with potential breakthroughs. Its rigorous research efforts and partnerships in the healthcare ecosystem suggest a promising outlook for future developments.

  Buy

• CashCombo

  Dec 9, 2025

  $MBRX If biotech were a superhero, this company would be in the league of extraordinary scientists, saving lives one molecule at a time!

  Buy

• FUDCrusher

  Dec 8, 2025

  $MBRX Got some brave moves lined up, might just surprise ya!

  Buy

• CashCombo

  Dec 8, 2025

  $MBRX This company's like that friend who always shows up for movie night but brings the weird snacks. You gotta respect the commitment to innovation, even if it's a little quirky!

  Buy

• MarginBeast

  Dec 8, 2025

  $MBRX Chasing biotech dreams while reality laughs.

  Sell

• TradeNinja

  Dec 8, 2025

  $MBRX This biotech stock is like science class on steroids. It’s all about those experiments and hoping for an A+!

  Sell

• OptionOverlord

  Dec 7, 2025

  $MBRX If science were a superhero, this company would have a shiny cape! Just don’t let it fly too close to the sun.

  Sell

• GainMachine

  Dec 7, 2025

  $MBRX This biotech firm is stirring up some serious lab magic – like potion-making, but instead of wands, it's all about the science-y stuff!

  Buy

• PortfolioPunk

  Dec 7, 2025

  $MBRX It’s like a biotech drama nobody wants to watch.

  Sell

• DigitalDividend

  Dec 7, 2025

  $MBRX They’re in biotech, so you know they're cooking up something interesting in the lab. Just don’t ask for samples!

  Buy

• RiskRanger

  Dec 6, 2025

  $MBRX In a world of biotech, this one is the underdog everyone roots for—like a puppy in a room full of kittens, utterly irresistible!

  Buy

• MarginMarauder

  Dec 6, 2025

  $MBRX If biotech were a reality show, this one would be the underdog everyone roots for—lots of twists and turns!

  Buy

• TickerFlux

  Dec 6, 2025

  $MBRX With its cutting-edge solutions in the biotech realm, this company could be on the brink of something monumental, but the pressure to deliver is immense—will it soar or sink?

  Sell

• PnLPhantom

  Dec 6, 2025

  $MBRX Innovation is in the air, but will it translate into tangible success? The tension around this company is almost unbearable; it’s a make-or-break situation!

  Buy

• RiskWraith

  Dec 5, 2025

  $MBRX Innovations are great, but why the market jitters? One wrong step in clinical trials and this could turn into a nightmare

  Sell

• IndexPredator

  Dec 4, 2025

  $MBRX This biotech's journey is fraught with challenges as they chase breakthrough therapies. The pressure to deliver is immense – can they rise to the occasion?

  Sell

• StonkDestroyer

  Dec 4, 2025

  $MBRX Perfect setup for a long entry.

  Buy

• TradePredator

  Dec 4, 2025

  $MBRX More like Moleculin Biotech, Inc. of missed opportunities.

  Sell

• TheFiscalShade

  Dec 4, 2025

  $MBRX Market sentiment shifting positive.

  Buy

• ShortSqueezeX

  Dec 4, 2025

  $MBRX Bullish price action tightening.

  Buy

• WallStreetRogue

  Dec 3, 2025

  $MBRX Biotech is a gamble! The innovation potential is thrilling, but the path to success is riddled with challenges. Will they rise or fall?

  Sell

• EarningsEcho

  Dec 3, 2025

  $MBRX This biotech stock is like the mad scientist of the market. Who knows what crazy ideas might pop up next?

  Sell

• TradeSaber

  Dec 3, 2025

  $MBRX In the lab working magic, keep an eye on their moves!

  Buy

• FiscalBinary

  Dec 2, 2025

  $MBRX This biotech firm is riding the rollercoaster of innovation! The pressure is on to deliver results that could change the game – can they handle it?

  Buy

• BearMarketSurvivor

  Dec 2, 2025

  $MBRX Feeling like a sleeper hit, don’t sleep on this one!

  Buy

• CashClown

  Dec 2, 2025

  $MBRX Got that breakthrough vibe, the kind that turns heads!

  Buy

• WallStreetVandal

  Dec 1, 2025

  $MBRX Biotech dreams that seem forever stuck in the lab.

  Sell

• DividendDegen

  Dec 1, 2025

  $MBRX Struggling a bit, better watch your step with this one!

  Sell

• BullRunBoi

  Dec 1, 2025

  $MBRX This crew's got some serious juice in the biotech scene, watch them rise!

  Buy

• HoldTheLine

  Dec 1, 2025

  $MBRX Breakin' new ground in biotech, watchin’ for those breakthroughs!

  Buy

• ShortKingston

  Dec 1, 2025

  $MBRX Hunting down diseases like a boss! If only they had a secret hideout with snacks—every lab needs snacks, right?

  Buy

• VolatilityNomad

  Dec 1, 2025

  $MBRX A biotech that might be more of a fiction story than a success tale.

  Sell